Generally no, not really but there is typically some small loss of coordination for me. It doesn't make me dizzy, per se, but it does make my movements a little off-kilter and I tend to be about 10% less confident if I'm out somewhere dancing.
@SpiralusSancti has it right, and I agree: "I'm not sure dizzy is the right word". Perhaps light ataxia? Idk.
The cure for this, of course, is dosing LSD, which gives my dancing confidence a +10% boost in the ~100 - 300 µg range. After that: all bets are off.
Ketamine, on the other hand, can give me the spins.
Are you arguing otherwise? Crystals are no longer formed when they are dissolved in water. You cannot have any polymorphs, or any crystal form whatsoever, if they are dissolved in solution. When a compound dissolves, its individual molecules or ions become uniformly distributed in the solution. The specific crystal structure is no longer relevant as the substance is now in a molecular or ionic form dispersed throughout the solvent.
However, crystal polymorphism can affect the dissolution rate of a compound. Different crystal forms may dissolve at different rates due to variations in surface area or crystal lattice energy. This could lead to slightly different dissolution profiles, but once fully dissolved, the compound behaves the same regardless of its previous crystal form.
In practical terms, for many applications, what matters most is the stability of the compound rather than its solubility w/r/t crystal polymorphism. This is how it affects the pharmaceutical industry in terms of drug patents.
While there are polymorphic forms of some drugs that can affect their pharmacodynamics, MDMA generally exists as a racemic mixture, and polymorphism probably does not play a significant role in its effects. I think what you're referring to is how the bioavailability of
certain compounds can be negatively impacted if one of its polymorphs is resistant to dissolution in the body. The rate at which this occurs can affect things sometimes, though generally I don't think this is the case with hydrophilic compounds like methamphetamine.hcl and 3,4-MDMA.hcl, both of which rapidly and copiously dissolve in H₂O. The primary factors influencing MDMA's pharmacodynamics are dosage, individual differences in enzyme profile, and external factors like environment and mindset, as you know.
Check this out. You might find this interesting ☞
Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)
Of relevance to the discussion:
MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? To wit: "The fraction of metabolic clearance regulated by CYP2D6 for both drugs is substantially lower than expected from in vitro studies. Other isoenzymes of cytochrome P450 and a relevant contribution of renal excretion play a part in their clearance. These facts tune down the potential contribution of CYP2D6 polymorphism in the clinical outcomes of both substances. Globally, the clinical relevance of CYP2D6 polymorphism is lower than that predicted by in vitro studies."